View as an RSS Feed
Portola's New Factor Xa Antidote Could Help Drive Xarelto And Eliquis Sales
- Portola's Factor Xa antidote has cleared the Phase III trial.
- Pfizer, Bristol-Myers Squibb, and Johnson & Johnson could all benefit from Portola's success.
- Portola's drug could possibly be used for Lovenox as well.
- New Research And Competition Could Hurt AbbVie's Other Blockbuster
- Eli Lilly Hopes To End Novo Nordisk's Stranglehold On The GLP-1 Market
- Why Momenta Offers A Unique Opportunity In The Pharmaceutical Industry
- An Update On Pfizer's Recently Approved Drugs
- Biosimilars Could Be An Unlikely Boost For Pfizer
- Questcor's Growth Could Lead To Its Downfall
- A Detailed Look At Abbvie
- Degludec And Liraglutide: 2 Drivers Of Novo Nordisk's Growth
- Jim Cramer Pumps Alkermes - Is He Right?
- AbbVie Beyond Humira
- Who Will Conquer The Oral Multiple Sclerosis Market?
- FDA Recommendations Bode Well For Pfizer
- Novartis: What Will Be Gilenya's Fate?
- Does Novo Nordisk's Pipeline Justify Its Premium?
- Why Novartis Is The Safest Stock In The Pharmaceutical Sector
- For Sale: Pfizer's Growth Prospects
- Replacing Coumadin: A $10 Billion Opportunity
- Best Selling Drugs Going Off Patent In 2012
- Novartis' Own Study Puts Tekturna On Its Death Bed
- Biosimilars Could Increase Earnings For Drug Manufacturers
- A Look At Pfizer's Pipeline For Candidates To Replace Lipitor's Lost Revenue
- AstraZeneca: Saturn Trial Will Hamper Revenue Growth